IMR Press / FBL / Volume 11 / Issue 1 / DOI: 10.2741/1838

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Viral Vectors for Cancer Immunotherapy

Show Less
1 Oxford BioMedica (U.K.) Ltd., Oxford Science Park, Oxford, OX4 4GA, United Kingdom
2 MNLpharma Ltd., University of Reading Science and Technology Centre, Whiteknights, Reading, Berks, RG6 6AH, United Kingdom
Academic Editor:Howard Kaufman
Front. Biosci. (Landmark Ed) 2006, 11(1), 804–817;
Published: 1 January 2006
(This article belongs to the Special Issue Cancer vaccine)

Over the last decade, immunotherapy approaches for the treatment of cancer have been investigated with renewed vigour, perhaps catalyzed by the clinical successes seen with monoclonal antibody and cytokine based therapies. The identification of tumor-associated antigens (TAAs) in multiple cancer types has enabled the development of targeted immunotherapies and allayed some of the safety concerns associated with the induction of deleterious autoimmune reactions. In addition to the TAA or therapeutic gene, the antigen delivery system is equally as important for the development of a successful cancer vaccine. One approach to induce a potent and targeted antitumor response is to use viruses to deliver the TAA to cells of the immune system. A diverse array of oncolytic viruses and recombinant viral vectors encoding numerous therapeutic genes or TAAs have been tested in pre-clinical studies and produced results which, in some cases, justify their clinical development as potential cancer immunotherapies. Within the last 5-10 years, many such recombinant vectors have made the transition from pre-clinical research to clinical development and it is these, which are given most weight in this review.

Back to top